Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | GRIN2D | O15399 | 4/20 | 0.39 |
| ▸ | GRIN3B | O60391 | 4/20 | 0.39 |
| ▸ | GRIN1 | Q05586 | 4/20 | 0.39 |
| ▸ | GRIN2A | Q12879 | 4/20 | 0.39 |
| ▸ | GRIN2B | Q13224 | 4/20 | 0.39 |
| ▸ | GRIN2C | Q14957 | 4/20 | 0.39 |
| ▸ | GRIN3A | Q8TCU5 | 4/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10514319 | 1.00 | PTGS1 (0.41) | PTGS1SLC7A11ALDH1A1ALOX15GRIN2D | |
| SCHEMBL826512 | 0.78 | GSR (0.45) | PTGS1SLC7A11ALDH1A1ALOX15GRIN2D | |
| SCHEMBL15634459 | 0.78 | GSR (0.45) | PTGS1SLC7A11ALDH1A1ALOX15GRIN2D | |
| SCHEMBL5003290 | 0.77 | — | — | |
| SCHEMBL4329736 | 0.77 | — | — | |
| SCHEMBL4329733 | 0.77 | — | — | |
| SCHEMBL1895924 | 0.77 | — | — | |
| SCHEMBL827021 | 0.75 | GRIK1 (0.39) | PTGS1SLC7A11 | |
| SCHEMBL5668298 | 0.75 | GSR (0.48) | ALOX15GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL231631 | 0.75 | GSR (0.48) | ALOX15GRIN2DGRIN3BGRIN1GRIN2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230158179-A1 | RADIOPHARMACEUTICAL CONJUGATE COMPOSITIONS AND USES THEREOF | RAYZEBIO, INC. | 2023-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230158179-A1 | RADIOPHARMACEUTICAL CONJUGATE COMPOSITIONS AND USES THEREOF | PAICS, LNPEP, DNPEP | PTGS1 4864/4885SLC7A11 26/4885ALDH1A1 3285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.